Illumina Inc. is set to provide its sequencing cancer companion diagnostic test kit to be used along with Amgen Inc.'s EGFR-targeting drug, Vectibix (panitumumab), which earned a supplemental approval for use as a first-line treatment in wild-type RAS metastatic colorectal cancer patients in combination with FOLFOX and as a monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin and irinotecan-containing chemotherapy.